CIK 0000818686
- Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 39148213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $32,872,026
- in 8 filings, $10.6M under 10b5-1 plans
Net −$32,872,026. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −130,000 | $8.22 | $1.1M | 1,386.51 |
| 2022-03-07 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −8,941 | $7.37 | $66K | 126,086.51 |
| 2022-03-05 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion | +23,764 | 135,027.51 | ||
| 2022-03-05 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion · Restricted Share Units | −23,764 | 71,293 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion | +51,488 | 116,996.51 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −18,020 | $7.48 | $135K | 98,976.51 |
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion | +18,905 | 117,881.51 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −6,618 | $7.48 | $50K | 111,263.51 |
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion · Restricted Share Units | −51,488 | 0 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion · Restricted Share Units | −18,905 | 18,906 | ||
| 2022-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Grant or award · Restricted Share Units | +140,750 | 140,750 | ||
| 2022-02-28 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion | +21,682 | 73,098.51 | ||
| 2022-02-28 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −7,590 | $8.14 | $62K | 65,508.51 |
| 2022-02-28 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion · Restricted Share Units | −21,682 | 43,366 | ||
| 2022-02-09 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion | +16,121 | 57,532.51 | ||
| 2022-02-09 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −6,116 | $9.06 | $55K | 51,416.51 |
| 2022-02-09 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion · Restricted Share Units | −16,121 | 0 | ||
| 2022-02-08 | Fridriksdottir Hafrun Executive VP, Global R&D | Grant or award · Restricted Share Units | +51,488 | 51,488 | ||
| 2021-08-10 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −50,860 | $9.95 | $506K | 41,411.51 |
| 2021-05-11 | Fridriksdottir Hafrun Executive VP, Global R&D | Exercise or conversion | +37,884 | 111,337.51 |
Page 1 of 5 · 95 trades